Risk of Severe COVID-19 Outcomes Among Patients with Rheumatoid Arthritis in the United States

Abstract Introduction Coronavirus disease 2019 (COVID–19) has infected over 22 million individuals worldwide. It remains unclear whether patients with COVID–19 and Rheumatoid Arthritis (RA) experience worse clinical outcomes compared to similar patients with COVID–19 without RA. Aim The aim of this study is to provide insights on how COVID–19 impacted patients with RA given the nature of the disease and medication used. Methods RA cases were identified via International Classification of Diseases (ICD) codes and COVID–19 cases by laboratory results in the U.S. based TriNetX network. Patients with COVID–19 and RA were propensity–score matched based on demographics with patients with COVID–19 without RA at a 1:3 ratio. A hospitalized sub-population was defined by procedure codes. Results We identified 1,014 COVID-19 patients with RA and 3,042 non-RA matches selected from 137,757 patients. The odds of hospitalization (non-RA:23%, RA:24.6%, OR:1.08, 95% CI: 0.88 to 1.33) or mortality (non-RA:5.4%, RA:6%, OR:0.93, 95% CI: 0.65 to 1.34) were not significantly different. The hospitalized sub-population included 249 patients with COVID-19 and RA and 745 non-RA matches selected from 21,435 patients. The risk of intensive care unit (ICU) admission (non-RA:18.8%, RA:18.1%, OR:0.94, 95% CI: 0.60 to 1.45), and inpatient mortality (non-RA:14.4%, RA:14.5%, OR:0.86, 95% CI: 0.53 to 1.40) were not significantly different. Conclusion We didn’t find evidence suggesting patients with COVID–19 and RA are more likely to have severe outcomes than patients with COVID–19 without RA. Key Messages – Patients with Rheumatoid Arthritis (RA) tend to be older, and often have co-morbidities which could put them at greater risk of severe COVID-19 outcomes. – This study is one of the largest studies of COVID-19 infected RA populations to date. We did not find increased risk of hospitalization, ICU admission, or mortality among RA patients vs. matched non-RA patients. – Patients previously exposed to anti-coagulants experienced higher risks of hospitalization and overall mortality. Extra attention is needed for treating such patients.